Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022
- Inventiva (NASDAQ: IVA) announced the design of Phase 2a combination trial of lanifibranor in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH).
- The trial will assess lanifibranor combined with Eli Lilly And Co's (NYSE: LLY) Jardiance (empagliflozin).
- The trial's primary efficacy endpoint is a change in Hemoglobin A1c (HbA1c) at the end of the 24-week treatment compared to baseline.
- Secondary endpoints include changes in liver enzymes, glycaemic and lipids parameters, inflammatory markers, and body fat composition.
- 63 patients with non-cirrhotic NASH and T2D will be randomized into the trial.
- The Company plans to initiate the trial in 1H of 2022, with top-line results in 2H of 2023.
- Related: Fast Track Status Expanded For Inventiva's NASH Treatment.
- Price Action: IVA shares closed at $15 on Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Non Alcoholic steatohepatitis Phase 2 TrialBiotech News Health Care Small Cap General
